Mineralys Therapeutics (NASDAQ:MLYS) Upgraded to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded Mineralys Therapeutics (NASDAQ:MLYS) from a "sell" to a "hold"; overall analyst coverage remains largely positive with six Buys, one Hold and one Sell, and an average rating of Moderate Buy with a mean price target of $49.14.
• Key operational catalysts include a Q4 earnings beat (EPS of −$0.40 vs. consensus −$0.57) and regulatory progress—NDA accepted and a PDUFA date set for Dec. 22, 2026 for lorundrostat—reducing near‑term approval timing risk.
• Insiders have been net sellers (342,919 shares worth about $11.8M sold in the last 90 days, including CEO/CFO sales), even as institutional investors own roughly 84% of the company and market cap is about $2.07B.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a note issued to investors on Sunday.

MLYS has been the topic of a number of other research reports. Bank of America raised their target price on shares of Mineralys Therapeutics from $46.00 to $51.00 and gave the stock a "buy" rating in a research note on Friday. Jefferies Financial Group reissued a "hold" rating and issued a $30.00 price objective on shares of Mineralys Therapeutics in a research note on Friday. Stifel Nicolaus raised their price objective on shares of Mineralys Therapeutics from $45.00 to $52.00 and gave the company a "buy" rating in a research report on Friday, December 19th. Weiss Ratings restated a "sell (d-)" rating on shares of Mineralys Therapeutics in a research note on Thursday, January 22nd. Finally, HC Wainwright set a $56.00 target price on shares of Mineralys Therapeutics and gave the stock a "buy" rating in a report on Tuesday. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $49.14.

Mineralys Therapeutics Stock Performance

NASDAQ:MLYS opened at $26.19 on Friday. The stock has a 50-day simple moving average of $30.45 and a two-hundred day simple moving average of $35.51. The firm has a market capitalization of $2.07 billion, a PE ratio of -11.05 and a beta of 0.57. Mineralys Therapeutics has a 52-week low of $10.44 and a 52-week high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.17. Equities analysts forecast that Mineralys Therapeutics will post -4.23 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Adam Scott Levy sold 10,758 shares of Mineralys Therapeutics stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $32.14, for a total value of $345,762.12. Following the sale, the chief financial officer directly owned 8,638 shares of the company's stock, valued at approximately $277,625.32. The trade was a 55.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Jon Congleton sold 16,236 shares of the business's stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $32.62, for a total value of $529,618.32. Following the completion of the sale, the chief executive officer owned 639,151 shares in the company, valued at $20,849,105.62. This represents a 2.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 342,919 shares of company stock worth $11,755,439 over the last 90 days. Corporate insiders own 25.56% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Simplify Asset Management Inc. purchased a new position in shares of Mineralys Therapeutics in the 3rd quarter worth $8,294,000. Geode Capital Management LLC increased its holdings in shares of Mineralys Therapeutics by 19.0% in the 2nd quarter. Geode Capital Management LLC now owns 954,560 shares of the company's stock worth $12,917,000 after buying an additional 152,560 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Mineralys Therapeutics by 29.8% during the 3rd quarter. Vanguard Group Inc. now owns 3,018,999 shares of the company's stock valued at $114,480,000 after buying an additional 692,550 shares in the last quarter. Citigroup Inc. lifted its holdings in shares of Mineralys Therapeutics by 501.7% in the 3rd quarter. Citigroup Inc. now owns 163,168 shares of the company's stock valued at $6,187,000 after acquiring an additional 136,050 shares during the last quarter. Finally, 22NW LP lifted its holdings in shares of Mineralys Therapeutics by 21.4% in the 2nd quarter. 22NW LP now owns 560,042 shares of the company's stock valued at $7,577,000 after acquiring an additional 98,698 shares during the last quarter. 84.46% of the stock is currently owned by institutional investors.

More Mineralys Therapeutics News

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: NDA accepted by FDA and PDUFA set (Dec. 22, 2026) for lorundrostat — formal regulatory review underway, which de-risks timing for potential approval and commercialization. GlobeNewswire: Q4 results & NDA acceptance
• Positive Sentiment: Q4 results surprised to the upside — reported EPS of ($0.40) vs. consensus ($0.57), suggesting operational execution beat expectations and reducing near-term downside to estimates. MarketBeat: Q4 earnings summary
• Positive Sentiment: Management is actively preparing for launch and payer engagement ahead of the regulatory decision — signaling commercialization planning and market-access work that could speed uptake if approved. Seeking Alpha: Launch & payer engagement
• Neutral Sentiment: Conference call and transcript provide management’s roadmap and data context (Q4 call reviewed NDA strategy, clinical data and next steps); useful for modeling but not a surprise item. Seeking Alpha: Earnings call transcript
• Neutral Sentiment: Press coverage highlights steady progress with FDA interactions and public messaging; these articles reiterate facts rather than deliver new catalysts. Yahoo Finance: FDA progress TipRanks: NDA acceptance overview
• Negative Sentiment: Critical commentary warns of potential interference from larger pharma interests that could complicate the approval or market dynamics — introduces regulatory and competitive risk that can pressure shares. Seeking Alpha: Concerns over big pharma pressure

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.